News
When it comes to weight loss, there are a number of tried and true lifestyle changes you can make to help you along the way.
As Sky News research revealed thousands of severely obese patients are facing severely delayed treatment, here we look at the ...
A study published in Cell Metabolism looks at the effects of semaglutide on skeletal muscle mass in mice. Prof Lora Heisler, Director of Research, Rowett Institute, University of Aberdeen, Rowett ...
57m
Barchart on MSNIs Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand ...
People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.
Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...
Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...
2h
Stocktwits on MSNNovo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny SideNYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...
People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...
Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...
People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results